Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. by Akyol, Mehmet Umut et al.
UCSF
UC San Francisco Previously Published Works
Title
Recommendations for the management of MPS VI: systematic evidence- and consensus-
based guidance.
Permalink
https://escholarship.org/uc/item/5pc012vk
Journal
Orphanet journal of rare diseases, 14(1)
ISSN
1750-1172
Authors
Akyol, Mehmet Umut
Alden, Tord D
Amartino, Hernan
et al.
Publication Date
2019-05-29
DOI
10.1186/s13023-019-1080-y
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH Open Access
Recommendations for the management of
MPS VI: systematic evidence- and
consensus-based guidance
Mehmet Umut Akyol1, Tord D. Alden2, Hernan Amartino3, Jane Ashworth4, Kumar Belani5, Kenneth I. Berger6,
Andrea Borgo7, Elizabeth Braunlin8, Yoshikatsu Eto9, Jeffrey I. Gold10, Andrea Jester11, Simon A. Jones12,
Cengiz Karsli13, William Mackenzie14, Diane Ruschel Marinho15, Andrew McFadyen16, Jim McGill17,
John J. Mitchell18, Joseph Muenzer19, Torayuki Okuyama20, Paul J. Orchard21, Bob Stevens22, Sophie Thomas22,
Robert Walker23, Robert Wynn24, Roberto Giugliani25* , Paul Harmatz26, Christian Hendriksz27, Maurizio Scarpa28,
MPS Consensus Programme Steering Committee and MPS Consensus Programme Co-Chairs
Abstract
Introduction: Mucopolysaccharidosis (MPS) VI or Maroteaux-Lamy syndrome (253200) is an autosomal recessive
lysosomal storage disorder caused by deficiency in N-acetylgalactosamine-4-sulfatase (arylsulfatase B). The heterogeneity
and progressive nature of MPS VI necessitates a multidisciplinary team approach and there is a need for robust
guidance to achieve optimal management. This programme was convened to develop evidence-based, expert-agreed
recommendations for the general principles of management, routine monitoring requirements and the use of medical
and surgical interventions in patients with MPS VI.
Methods: 26 international healthcare professionals from various disciplines, all with expertise in managing MPS VI,
and three patient advocates formed the Steering Committee group (SC) and contributed to the development of this
guidance. Members from six Patient Advocacy Groups (PAGs) acted as advisors and attended interviews to ensure
representation of the patient perspective. A modified-Delphi methodology was used to demonstrate consensus among
a wider group of healthcare professionals with expertise and experience managing patients with MPS VI and the
manuscript has been evaluated against the validated Appraisal of Guidelines for Research and Evaluation (AGREE II)
instrument by three independent reviewers.
Results: A total of 93 guidance statements were developed covering five domains: (1) general management principles;
(2) recommended routine monitoring and assessments; (3) enzyme replacement therapy (ERT) and hematopoietic
stem cell transplantation (HSCT); (4) interventions to support respiratory and sleep disorders; (5) anaesthetics and surgical
interventions. Consensus was reached on all statements after two rounds of voting. The greatest challenges faced by
patients as relayed by consultation with PAGs were deficits in endurance, dexterity, hearing, vision and respiratory
function. The overall guideline AGREE II assessment score obtained for the development of the guidance was 5.3/7
(where 1 represents the lowest quality and 7 represents the highest quality of guidance).
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Conclusion: This manuscript provides evidence- and consensus-based recommendations for the management of
patients with MPS VI and is for use by healthcare professionals that manage the holistic care of patients with the
intention to improve clinical- and patient-reported outcomes and enhance patient quality of life. It is recognised that
the guidance provided represents a point in time and further research is required to address current
knowledge and evidence gaps.
Keywords: Maroteaux-Lamy syndrome, Mucopolysaccharidosis, MPS VI, Management guidelines, Galsulfase,
Enzyme replacement therapy, ERT, Haematopoietic stem cell transplantation, HSCT, Surgery, Anaesthetics
Background
Mucopolysaccharidoses (MPS) are part of a clinically het-
erogeneous group of diseases known as lysosomal storage
disorders (LSDs), of which there are over 60 different
types. Symptoms of MPS occur because of deficiencies in
enzymes that break down glycosaminoglycans (GAGs) [1–
3]. Eleven different enzymes are responsible for the step-
wise degradation of GAGs, deficiencies in each of which
are responsible for seven different types of MPS [4]. Pa-
tients with MPS typically seem healthy at birth, but symp-
toms usually appear during early childhood as the
concentration of GAGs in cells increases. The pursuant ef-
fect on tissues and organs cause severe morbidity and re-
duced life expectancy [5, 6]. Clinical features can vary
according to MPS subtype, but coarse features, organome-
galy, skeletal and joint abnormalities, dysfunction in vision
and hearing and cardiorespiratory problems are common
across all MPS subtypes [1].
MPS VI or Maroteaux-Lamy syndrome (253200) is an
autosomal recessive MPS disorder caused by deficiency in
N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ASB; EC
3.1.6.12). Birth prevalence has been reported to range from
1 in 43,261 live births in Turkish immigrants living in
Germany [7] to 1 in 1,505,160 live births in Sweden [8, 9].
ASB catalyses the breakdown of dermatan sulphate, which
is present particularly in the skin, but is also found in ten-
dons, blood vessels, airways and heart valves [10]. Preclin-
ical data have shown that dermatan sulphate effects an
inflammatory response via the tumour necrosis factor
(TNF) pathway, and its accumulation results in apoptosis of
chondrocytes and ensuing progressive arthropathy [11, 12].
MPS VI is classified according to severity of symptoms
and is typically termed as being either slowly or rapidly
progressing; however, it is now known that an intermedi-
ate form between slowly and rapidly progressing MPS also
exists. Presentation differs according to age of onset and
velocity of disease progression; and higher urinary GAG
levels are associated with rapidly progressing disease [13].
However, a large number of mutations of the ASB gene
have been identified and are believed to be responsible for
the heterogeneity in presentation [9]. Although elevated
urinary GAGs and increased dermatan sulphate
concentrations are markers of the disease, these alone do
not provide a definitive diagnosis. Diagnosis is generally
accepted by confirmation in an accredited laboratory of
ASB enzyme activity in cultured fibroblasts or isolated leu-
kocytes of < 10% of the lower limit of normal and/or dem-
onstration of two disease-causing mutations [9, 14, 15].
Symptoms of MPS VI include decreased growth velocity,
coarse facial features, skeletal deformities, frequent
upper-airway infections, enlarged liver and spleen, hearing
loss, joint stiffness and coarse hair [14]. Abnormalities of
cardiac valve anatomy and function are present in all pa-
tients with MPS VI [16] and are attributed to the depos-
ition of dermatan sulphate within the cardiac valves.
MPS are rare diseases; therefore, the small patient
population of patients with MPS VI precludes the gener-
ation of large datasets through participation in Phase 3 tri-
als, and consequently the availability of top-level evidence
through meta-analyses. Although guidance for MPS VI
has been published [14], owing to the lack of available evi-
dence, the provision of credible guidelines in rare diseases
requires the use of robust methodology to provide expert-
driven, consensus-based guidance. The guidance provided
in this manuscript represents a transition from expert
opinion in prior documents to a validated approach that
includes a comprehensive literature review and a modified
Delphi process.
Objectives
The scope of the programme was to develop guidance for
the management of two MPS without neurocognitive
manifestations, namely MPS IVA and MPS VI. This
manuscript provides robust evidence- and consensus-
based guidance for the management of adult and paediat-
ric patients with MPS VI. The guidance is comprised of a
holistic set of recommendations for the timely and appro-
priate use of medical and surgical interventions and man-
agement of the natural history of MPS, with the intention
to maintain and enhance patient quality of life and im-
prove clinical- and patient reported- outcomes. The guid-
ance is intended for use by healthcare professionals who
manage the care of patients with MPS VI, in particular
paediatricians and geneticists, and aims to enhance
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multidisciplinary practice across specialisms. It also pro-
vides specific guidance for other specialists (Table 1) and
stakeholders in the health services who are in contact with
patients with MPS and is a useful reference for patient ad-
vocates, patients and their families. Table 1 describes the
areas of clinical focus covered within this guidance and
the corresponding recommended speciality focus.
This guidance was developed as part of a broader con-
sensus programme that also covered the management
of MPS IVA, the results of which are published in a com-
panion article (Recommendations for the management
of MPS IVA: systematic evidence- and consensus-based
guidance).
Methods and process
As the methodology for guidance pertaining to both
MPS IVA and MPS VI consensus was conducted in par-
allel, the full methodology is reported in a companion
article: Recommendations for the management of MPS
IVA: systematic evidence- and consensus-based guidance.
Briefly, the methodology included: a systematic expert
mapping process to identify the programme Co-Chairs; rec-
ommendations from the Co-Chairs to align the inter-
national Steering Committee (SC) group; numerous
face-face and online SC meetings to define the clinical
questions to be answered by the guidance according to the
P.I.C.O methodology (Additional file 1: Appendix 1a); a sys-
tematic literature review to identify the evidence base for
each clinical question in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (Additional file 1 Appendices 1b and
1c) [17]; assessment of the quality of evidence level for each
paper using the Oxford Centre for Evidence-based Medi-
cine criteria (Additional file 1: Appendix 2 and Add-
itional files 2 and 3); consultations with six global Patient
Advocate Groups (PAGs) [listed in the acknowledgements
section of the manuscript] to generate insights to inform
the development of guidance statements; drafting of guid-
ance statements by the SC via a series of face-to-face, online
meetings and email correspondence; validation of the guid-
ance statements by a modified-Delphi survey [18, 19] (the
full results including the number of voters/statement, re-
spondent specialisms and geographies, and respondent
feedback to guidance statements are included within Add-
itional files 4 and 5); grading of recommendation state-
ments based on the average evidence level for each
supporting reference (Additional file 1: Appendix 2 and
Additional files 2 and 3) and independent assessment of the
manuscript by three reviewers using the Appraisal of
Guidelines for Research and Evaluation (AGREE) II Instru-
ment [20] (full information including the scores from the
two rounds of AGREE II evaluation can be found in Add-
itional file 1: Appendix 3).
The SC consisted of four Co-Chairs and a further 22
healthcare professionals were convened from a wide
geographic spread covering multiple medical specialties
including: anaesthesia, ear, nose and throat (ENT) surgery,
cardiology, endocrinology, genetics, hand surgery,
Table 1 Clinical areas of focus and recommended speciality focus
Table Recommended speciality focus
Table 2: General principles for the management of patients with MPS VI all
Table 3: Recommended routine monitoring and assessments in patients
with MPS VI
all
Table 4: Guidance statement for galsulfase geneticist, metabolic physician, paediatrician, nurse,
physiotherapist
Table 5: Guidance statements for HSCT anaesthetist, bone marrow transplant expert/hematopoietic
stem cell transplant expert, geneticist, paediatrician, nurse
Table 6: Guidance statements for continuous positive airway pressure
(CPAP), non-invasive positive pressure ventilation (NIPPV), oxygen
supplementation and hypercapnia monitoring
anaesthetist, ear-nose-throat specialist, geneticist, paediatrician,
respiratory physician/pulmonologist, nurse
Table 7: Guidance statements for anaesthesia all
Table 8: Guidance statements for hip reconstruction, hip replacement
and growth modulation surgeries
anaesthetist, geneticist, orthopaedic surgeon, neurosurgeon,
paediatrician, physiotherapist
Table 9: Guidance statements for decompression of the spinal cord,
spinal stabilisation and thoracolumbar kyphoscoliosis
anaesthetist, geneticist, orthopaedic surgeon, neurosurgeon,
paediatrician, physiotherapist
Table 10: Guidance statement for corneal transplantation anaesthetist, geneticist, ophthalmologist, paediatrician
Table 11. Guidance statements for decompression of the median
nerve, tenosynovectomy and pulley release
anaesthetist, geneticist, hand surgeon, orthopaedic surgeon,
neurosurgeon, paediatrician
Table 12: Guidance statement for cardiac valve replacement and left
ventricular apical aneurysms
anaesthetist, cardiologist, geneticist, paediatrician
Table 13: Guidance statements for tonsillectomy and/or adenoidectomy,
tracheostomy and insertion of ventilation tubes
anaesthetist, geneticist, ear-nose-throat specialist, paediatrician,
respiratory physician/pulmonologist
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haematopoietic stem cell transplantation (HSCT), neuro-
surgery, ophthalmology, orthopaedic surgery, paediatrics,
pain management and pulmonology. To ensure the patient
view was considered, three representatives from PAGs also
formed part of the SC group. The SC defined the scope of
the programme, identified the medical and surgical inter-
ventions to be covered in the guidance and provided
search terms for the literature review. More information
about the SC, including their details, competing interests
and contributions can be found in the declarations section
of the manuscript.
Setting the clinical questions to be answered by the
guidance
The SC group developed the clinical questions to be
answered by the guidance according to the patient, inter-
ventions, comparator and outcome (P.I.C.O.) method-
ology (outlined in Additional file 1: Appendix 1a) and are
shown below.
1. What are the general principles for the
management of adult and paediatric MPS VI?
2. What are the recommended routine monitoring
and assessments that should be used to track the
natural history of adult and paediatric MPS VI
and indicated interventions to be used in the
management of the common symptoms of MPS VI?
3. For patients with adult and paediatric MPS VI,
what is the impact on clinical outcomes and safety/
tolerability of:
 Interventions that address the underlying
enzyme deficiency
◦ ERT
◦ HSCT
 Interventions used to manage the symptoms
of MPS
◦ Respiratory and sleep disorders
◦ Anaesthetics
◦ Limb and spinal surgeries
◦ Ophthalmic surgeries
◦ Cardio-thoracic surgeries
◦ ENT surgeries
The programme also had a secondary focus to highlight
current evidence gaps and provide recommendations for fu-
ture treatment directions. This programme did not cover
the following topics: diagnosis, validation of new clinical
outcome assessment tools (e.g. to assess patient-reported
outcomes) and defining minimal clinically important differ-
ences for MPS IVA/VI.
Measures to address independence
The programme was funded by BioMarin; however, they
remained uninvolved throughout the whole process and did
not influence the scope or content of the programme. The
funder was absent from all SC meetings, remained blinded
to the guidance statements and was not involved in the pub-
lication process. An independent secretariat (Lucid Partners
Ltd) managed the programme and provided editorial sup-
port. The SC led the scope and content of the programme,
including the development of guidance statements. Conflicts
of interests for all SC members (found in the declarations
section) were recorded at the start of the programme and
updated throughout the programme. Following the system-
atic expert mapping exercise, it was noted that some of the
SC had previously worked on a consultancy basis with the
programme sponsor, who hold the marketing authorisation
for approved pharmaceutical therapy in MPS VI. Efforts
were therefore taken to ensure representation from leading
experts across other treatment modalities, including HSCT/
BMT on the Steering Committee panel and during the
modified-Delphi voting process, where a large number of
physicians across multiple specialisms and geographies were
engaged. At several stages during the process, the SC were
also required to provide updated conflict of interest
disclosures.
Results
The results of the modified-Delphi voting process are
described in more detail in the companion publication
(Recommendations for the management of MPS IVA: sys-
tematic evidence- and consensus-based guidance.
After two rounds of anonymised voting via an online sur-
vey (from a pool of 197 MPS physicians across 35 clinical
areas of focus in 25 countries worldwide), consensus was
reached on 94 validated guidance statements pertaining to
the management of patients with MPS VI (further informa-
tion about the modified-Delphi process, including: the num-
ber of voters/statement, respondent specialisms and
geographies, and respondent feedback to guidance state-
ments are shown in Additional files 4 and 5).
Three independent reviewers (listed in the acknowledge-
ments section of the manuscript) assessed the guidance for
methodological rigour and transparency against the vali-
dated Appraisal of guidelines for research and evaluation
(AGREE II) instrument. The guidance documents were
given an overall guideline assessment score of 5.3/7 (where
1 represents the lowest quality, and 7 represents the highest
quality). Full information including the assessment scores
across each domain criteria are outlined in Additional file 1:
Appendix 3.
Guidance statements
General principles (Table 2)
The diagnosis of MPS VI was deemed out of scope for this
guidance, but details can be found elsewhere [14, 15]. The
SC noted that if newborn screening is made available, this
would facilitate earlier diagnosis and intervention for
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patients with MPS VI, which is likely to change the course
of their disease. As the most serious surgical complications
occur in patients with advanced MPS, surgical procedures
(particularly airway procedures) where indicated, should be
conducted as soon as possible. Guidelines for pain
management in patients with MPS have recently been pub-
lished [21, 22].
Recommended routine monitoring and assessments (Table 3)
Disease-modifying interventions
ERT (galsulfase) in patients with MPS VI (Table 4)
Rationale and evidence base Galsulfase is a recombin-
ant form of human lysosomal enzyme N-acetylgalactosa-
mine 4-sulfatase, an enzyme that is deficient in patients with
MPS VI. Treatment with galsulfase aims to transiently
restore N-acetylgalactosamine 4-sulfatase activity, thereby
preventing the accumulation of GAGs in lysosomal com-
partments of cells, which causes the clinical manifestations
of MPS VI [40]. It is currently the only disease-specific treat-
ment for MPS VI that is licensed and has been validated in
clinical trials and long-term post-marketing surveillance
studies [41–44]. Administration in patients with high base-
line urinary GAG levels resulted in a statistically significant
increase in height Z-score from pre-treatment baseline to
last follow-up for those beginning treatment at 0–3, > 3–6,
> 6–9, > 9–12, and > 12–15 years of age [44]. Galsulfase has
been shown to improve endurance (as measured by the 6
min walk test [MWT], 12MWT and 3-min stair climb
[3MSC]) [25, 40, 41, 45–49] and pulmonary function (as
measured by increases in forced vital capacity [FVC] and
forced expiratory volume [FEV1]), which may, in part, be at-
tributed to growth in young patients [41]. Results suggest
that if initiated early (in patients under 16 years of age),
galsulfase also results in an improvement in growth velocity,
although comparative data in patients who have not
received ERT are limited [41–44]. When initiated early
(in patients under 12 years of age), long-term treatment
with ERT is effective in preventing the progression of
cardiac valve abnormalities; however, the resultant effect
on cardiac outcomes is equivocal [50, 51]. There is a trend
for improvement in spleen and liver size [42, 52–54], facial
dysmorphia [54], joint mobility and decreased pain [40,
Table 2 General principles for the management of patients with MPS VI
Statement Percentage
consensus
All guidance statements are evidence Grade D (level 5 expert clinical opinion)
Diagnosis of MPS VI during infancy is critical to optimise patient outcomes 98%
The first consultation should be conducted by a physician with experience of treating MPS as soon as possible after diagnosis.
This should include a full discussion of disease pathology, progression, treatment options and management. Ongoing
information should be provided to optimise patient outcomes
97%
Patients and caregivers should receive ongoing psychosocial support from a social worker and/or psychologist, and should be
directed towards a MPS society or relevant patient organisation in their country
94%
A comprehensive medical history and multi-system evaluation should be conducted within days of diagnosis to set a
baseline for ongoing assessments and evaluate the physical and neurological manifestations of disease, functional ability
and disease burden
88%
Ongoing and regular multi-system monitoring, and assessments are recommended to track the natural history of MPS VI,
monitor the impact of treatment and assess the need for treatment interventions to manage the symptoms of MPS VI.
These should be conducted at every clinic visit, annually or in some cases as clinically indicated (for example pre- and
post-operatively)
100%
Timely interventions are recommended where clinically indicated by monitoring, to help avoid irreversible damage caused
by the natural history of MPS VI, and to manage the disease manifestations and maintain long-term quality of life (QoL)
99%
A multidisciplinary team (MDT) of metabolic specialists, surgeons and allied healthcare professionals (including, but not
limited to: nurses, physiotherapists, occupational therapists, psychologists and audiologists) is required to manage the
diverse range of disease manifestations of MPS VI
99%
Co-ordination of the entire MDT care team is required prior to any procedure to determine the need for surgery, to discuss
the benefits and risks of combining surgeries to minimise the need for multiple anaesthetics and to decide the optimal order
of procedures. The decision to combine surgeries should take into consideration the surgical and intubation time, and
complexity of procedures
93%
The risks and benefits of any intervention and the competing risks of other medical problems should be assessed and
discussed with patients, families and caregivers such that they can make an informed decision on the appropriateness of
the therapy/surgery
100%
Surgical procedures should be performed by (or under the guidance of) specialist surgeons and anaesthetists with experience
of MPS, in medical centres with intensive care units
99%
Management of pain should be a fundamental part of the care of patients with MPS VI, with the aim of improving QoL
and maintaining mobility. Refer to general guidelines for pain management
100%
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Table 3 Recommended routine monitoring and assessments in patients with MPS VI
Statement Percentage
consensus
All guidance statements are evidence Grade D (based on level 5 expert clinical opinion), unless otherwise stated
Physical examination
A physical examination should be performed during every visit to assess general health, growth, vital signs, abdominal
organ size, presence of hernia, neurologic function (including gait), joint stiffness, and functions of the eyes, ears, heart
and lungs
90%
Routine physical examination can also identify signs of potential respiratory problems, such as an enlarged tongue or
sniffing position
90%
Radiology
While X-rays are essential to identify the natural history of disease and response to treatment, efforts should be made
to minimise radiation exposure, and images should be requested only when clinically useful
85%
Hips: an anteroposterior (AP) pelvis radiograph should be performed at diagnosis and as clinically indicated (based on
physical examination or reports of pain) to quantify hip dysplasia or identify early signs of hip migration [23]
88%
Lower limbs: in patients with clinical evidence of valgus deformity of the lower limbs, standing AP radiographs of lower
extremities should be performed prior to guided growth surgery [24]
100%
Spine: standing or sitting plain radiography of the cervical and thoracolumbar spine to examine for spinal deformities is
recommended in patients with MPS VI at diagnosis and every 2–3 years thereafter, or sooner if clinically indicated [24]
Evidence Grade: C (level 3/4 studies)
85%
Magnetic resonance imaging (MRI) of the whole spine (in neutral position) should be performed annually in children
with MPS VI to assess for spinal cord injury. The frequency may be reduced for adult patients with stable imaging
who do not display symptomsa
84%
Flexion/extension MRI of cervical spine may be needed to identify changes in spinal canal and spinal cord 86%
MRI of the brain is recommended at diagnosis in patients with MPS VI, and should be repeated as needed in individuals
with clinical suspicion of hydrocephalus
80%
MRI of the brain and spinal cord in patients with MPS VI may require sedation or general anaesthesia depending on patient
age and cooperation. General anaesthesia carries substantial risk for patients with MPS
95%
Flexion/extension computerised tomography (CT) of the craniocervical junction may be considered in individuals with MPS
VI if MRI is not available or if sedation is not possible
92%
The presence of specific radiological signs may indicate the need for surgical intervention to correct skeletal deformities;
however, there is insufficient evidence to support preventative surgery based on radiological findings
88%
Endurance
Choice of assessment depends on the patient’s physical and developmental ability [25] 97%
Baseline assessment is the most important and ideally two values should be obtained as a minimum. Consistent protocols
should be used when performing repeat measurements to minimise variability
95%
Annual endurance testing using 6-min walk test (6MWT) is recommended, as per the American Thoracic Society guidelines
[13, 25, 26]
87%
In patients with limited ambulation who are unable to perform the 6MWT, endurance should be assessed via alternative
methods such as an adapted timed 25-ft walk test (T25FW)
76%
Endurance testing is also recommended prior to initiation of ERT and annually thereafter as a measure of treatment efficacy
and to provide early evidence of possible neurologic or skeletal issues
87%
Growth
Assessment of growth should be performed at each clinic visit as part (ideally every 6 months) of a regular physical examination
and should include: standing height (sitting height if the patient is unable to stand), length (supine position), weight, head
circumference (≤3 years), Tanner pubertal stage (until maturity)
95%
Height and weight should also be measured before initiation of ERT and at every clinic visit thereafter (ideally every 6 months) to
evaluate the impact of treatment
95%
Urinary glycosaminoglycan (uGAG) levels
Urinary GAG levels should be tested prior to starting galsulfase and every 6 months thereafter to determine the pharmacodynamic
effects of ERT [13]
Evidence Grade: C (level 3/4 studies)
97%
Measurement of total uGAG levels may be performed using standard dye-based quantitative methods, preferably in the same
laboratory and assessed against age-related reference values
93%
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Table 3 Recommended routine monitoring and assessments in patients with MPS VI (Continued)
Statement Percentage
consensus
Where available tandem mass spectrometry may be used to assess levels of specific GAGs (such as dermatan sulphate) b [27–32]
Evidence Grade: C (level 3/4 studies)
97%
Cardiac function
Initial cardiac evaluation should be performed at the time of diagnosis and include assessment of vital signs with measurement
of oxygen saturation, right arm and leg blood pressure measurements, careful auscultation, full transthoracic two-dimensional
and Doppler echocardiogram, and 12-lead electrocardiogram (ECG) [33]
100%
Longer ECG monitoring (prolonged Holter/event monitoring) may be considered in older patients, especially if they have
symptoms of black outs, unexpected falls or dizziness
96%
Follow-up in expert centres should be annually initially, but may be extended to every 2–3 years if there is no evidence of cardiac
abnormality [34, 35]
92%
Additional cardiac assessment, including a standard ECG, should be performed prior to any surgical procedure requiring general
anaesthesiac [34, 35]
92%
Neurological exam
A detailed neurological examination should be performed at every clinic visit (minimally every 6 months) and, where possible
these should correlate with imaging studies of the spine to detect early spinal stenosis or instability compromising the cervical
cord. For patients without clinical or radiographic concern, annual neurological examination may be sufficient [36]
87%
Standard MRI of the cervical spine should be performed to assess for presence of spinal cord compression. In the absence of
significant spinal cord compression, proceed with flexion/extension MRI to confirm the presence of worsening spinal cord
compression with motiond
78%
Upper limb function
Symptoms of carpal tunnel syndrome (CTS) are often atypical in patients with MPS VI, therefore recommend clinical examination,
assessment of range of finger movement and strength, electrophysiology nerve conduction assessment and detailed medical history
to be performed at diagnosis and annually thereafter
89%
Standardized clinical examination, assessment of active and passive range of movement and nerve conduction studies (NCS) are
recommended to assess hand and upper limb function in individuals with MPS VI
89%
Respiratory function and sleep disorder
Evaluation of respiratory function by spirometry, including forced vital capacity (FVC) and maximum voluntary ventilation (MVV),
should be performed to assess changes in lung volume and obstruction in children over 5 years of age
97%
Respiratory function should be assessed annually until children stop growing, and every 2–3 years thereafter, provided that respiratory
symptoms remain unchanged. Additional testing should be performed if respiratory symptoms change or if intercurrent illnesses
occur
91%
Normative values are not available, therefore change in absolute volume from patient’s own baseline will be the best indicator of
deterioration or improvement
97%
Measurement of respiratory rate and arterial oxygen saturation before and after annual endurance testing is recommended 86%
Evaluation of gas exchange and respiratory function is also recommended before any planned air travel, to ensure safety during
the flight
86%
To identify symptoms of sleep apnoea, patients should be asked to report presence of snoring and morning headaches at every clinic
visite
100%
Overnight sleep study (polysomnography) is recommended at diagnosis (if possible, and no later than 2 years of age), and every 3
years thereafter or when signs and symptoms of obstructive sleep apnoea (OSA) are noted [37, 38]
94%
Ear-nose-throat (ENT)
ENT examination, including tympanometryf, should be conducted every 3–6 months during childhood and every 6–12 months
thereafter
91%
ENT examination in patients with MPS VI should include visualization of the upper respiratory tract to determine diagnosis,
management and assist in pre-operative planning. Endoscopic examinations should be recorded and kept, to monitor disease
progression
92%
Fibreoptic examination in patients with MPS VI should be performed at diagnosis and at least annually thereafter, or as clinically
indicated. For those individuals who require general anaesthesia, ENT examination should be performed during the pre-operative
evaluation for other surgical procedures
83%
Upper airway CT, focused on airway anatomy preferably with reconstruction, may be useful to identify the area of the abnormality
and possible cause of obstruction in patients with MPS VI with suspected obstruction or malaciag
92%
Age-adjusted audiometric assessment as a baseline objective hearing evaluation should be conducted in the first clinic visit and
repeated annually to assess conductive and sensory-neural hearing loss [39]
100%
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52, 53, 55], and findings are suggestive of slowing of
bone disease progression [56].
The most common adverse events reported in the galsul-
fase clinical studies include pyrexia, rash, pruritus, urticaria,
chills/rigors, nausea, headache, abdominal pain, vomiting
and dypsnoea. Serious adverse reactions included laryngeal
edema, apnoea, pyrexia, urticaria, respiratory distress, an-
gioedema, asthma and anaphylactoid reaction. Infusion-as-
sociated reactions (IARs), defined as adverse reactions
occurring during galsulfase infusions or until the end of the
infusion day, were observed in 33 (56%) of the 59 patients
treated with galsulfase across five clinical studies [57, 58].
Table 3 Recommended routine monitoring and assessments in patients with MPS VI (Continued)
Statement Percentage
consensus
If speech problems are determined during ENT examination, an assessment by a speech pathologist should be conducted 100%
Balance tests should be conducted if the patient has a history of balance problems 95%
Ophthalmological function
Age-appropriate evaluations by an ophthalmologist is recommended every 6 months if possible, or at least annually 90%
Ophthalmic assessment may include visual acuity, refraction, slit-lamp examination of cornea, funduscopic evaluation including
optic nerve, and measurement of intraocular pressure
100%
Intraocular pressure monitoring and pachymetry may be considered prior to corneal transplant 100%
Evaluation of oral health by dentist
Recommend close monitoring of dental development (at least annually) to prevent caries and attrition as is monitoring of
occlusion and chewing functions
100%
The need for subacute bacterial endocarditis (SBE) prophylaxis prior to dental procedures should be assessed by a cardiologist 100%
Disease burden
Annual assessment of patient-reported outcomes is recommended for: pain severity, QoL (as assessed by reproducible and age-
appropriate questionnaires [e.g. EQ-5D-5 L]), fatigue, and activities of daily living (ADL; as assessed by functional tests [6MWT/T25FW])
and age-appropriate ADL questionnaires (e.g. MPS Health Assessment Questionnaire [MPS HAQ]), and assessment of wheelchair/
walking aid use
97%
These assessments may have to be adapted both for language, culture, and individual physical limitations as they have not been
validated in the specific disorders
97%
Physical therapy
Regular assessments by a physical therapist (lower limb), occupational therapist (upper limb) and rehabilitation medicine specialist
should be conducted to assess upper and lower limb function and provide support as needed
93%
The physical therapist could also assist in suggesting walking aids and other adaptations that may improve QoL 98%
Post-consensus comments by the SC to be taken into consideration
aMagnetic resonance imaging (MRI) can also be used to assess for spinal cord compression. The frequency may be reduced for older patients with stable imaging
who do not display symptoms
bTandem mass spectrometry may also be used to assess disease specific oligosaccharides [32]
cEchocardiogram (ECHO) should also be performed prior to any surgical procedure requiring general anaesthesia
dThis topic was discussed in detail with the neurosurgical and orthopaedic colleagues in the SC group. It was their expert clinical opinion that flexion/extension
MRI is not dangerous to perform within the hands of an experienced team. It is important that the range of motion (ROM), flexion and extension of the patient is
evaluated while they are awake immediately before anaesthesia. The ROM during anaesthesia should not exceed the ROM as noted in the awake state, and
should only be carried out after it is confirmed that there is no spinal cord compression. See Table 9 for guidance statements on spinal surgeries including spinal
cord decompression
eSigns and symptoms for sleep apnoea (a type of sleep disordered breathing (SDB)) can be divided into nocturnal and daytime symptoms. Nocturnal symptoms
include loud snoring, observed episodes of breathing cessation during sleep, abrupt awakenings accompanied by gasping or choking, and awakening with a dry
mouth or sore throat. Daytime symptoms include excessive daytime sleepiness, morning headaches, difficulty concentrating during the day, personality and mood
changes including depression or irritability, and high blood pressure. To identify presence of SDB, patients should be asked to report snoring and other signs and
symptoms of SDB at every clinic visit
fTympanometry is used to measure the volume of the ear canal/tympanic membrane movement and indirectly assess for fluid accumulation and opening of
pressure equalising tubes
gUpper airway CT may also be useful to identify the area of the abnormality and possible cause of obstruction in patients with MPS VI
Table 4 Guidance statement for galsulfase
Statement Percentage
consensus
Initiation of long-term ERT with galsulfase at a dose of 1 mg/kg/week by intravenous infusion is recommended in
patients with MPS VI as soon as possible after a confirmed diagnosis
Evidence Grade: B (level 2/3/4 studies)
89%
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The safety and superior efficacy of galsulfase when ad-
ministered from a young age has been demonstrated in
several sibling-controlled studies [59–61]. However,
most available data are from patients who initiate ERT
later in the course of disease and additional studies are
warranted to determine the long-term outcomes of gal-
sulfase treatment when administered from an early age.
Considerations prior to starting ERT Patient status,
disease burden and ultimate prognosis at the time of diagno-
sis must be accounted for when deciding the timing for initi-
ation of ERT. Initial administration of galsulfase should be
performed (where possible) by a clinician with experience of
metabolic disorders and in an infusion centre or hospital
with the necessary facilities to effectively manage IARs/ana-
phylactic reactions, should this be required. Home infusion
may be considered in regions where this is available; this de-
cision should be made by both the physician and patient.
Careful patient selection, good vascular access and a detailed
management plan for IARs/anaphylaxis are essential for the
success of this approach. Consideration should be given to
the need for a totally implantable vascular access device
(TIVAD) to facilitate long-term venous access for frequent
or continuous administration of ERT. Patients and their
families should be made aware of the benefits and risks of
using such a device as outlined in two case series [62, 63].
Considerations for monitoring response Baseline and
follow-up assessments to measure treatment efficacy
should be performed prior to and regularly after initiation
of galsulfase. These should include GAG/dermatan
sulphate concentration, endurance testing, upper limb
function, respiratory function (if age-compatible), growth,
height and weight, pain, activities of daily living (ADL)
and quality of life (QoL). It is important to assess the
life-long impact of galsulfase on an individual basis, as the
benefits of treatment may not be consistent across all pa-
tients [43, 64].
Considerations for managing specific adverse events
Due to the potential for hypersensitivity reactions with
galsulfase, patients who were treated with galsulfase in
the clinical trial programmes received antihistamine pre-
medication, with or without antipyretics, 30–60 min
prior to the start of the infusion. Owing to concerns
about the risk of hypersensitivity reactions with galsul-
fase, this approach is broadly followed in clinical prac-
tice; however, there is limited evidence in support of the
necessity of premedication use. Patients should be
closely observed for signs of anaphylaxis during and
after administration of galsulfase and if suspected, hos-
pital admission is advised. IARs are generally manage-
able by reducing the rate of administration or by
temporary interruption of the infusion and the adminis-
tration of additional antihistamines and antipyretics.
Due to the risk of sleep apnoea in patients with MPS VI,
use of a non-sedating antihistamine is recommended.
HSCT in patients with MPS VI (Table 5)
Rationale and evidence base The strongest data sup-
porting the role of HSCT as a treatment for MPS is de-
rived from subtypes other than VI; specifically, MPS IH
(Hurler disease) [65, 66]. HSCT is currently the standard
of care in patients with MPS IH because of its associated
improvement in central nervous system (CNS) disease,
which is not effectively treated by ERT [66–70]. The in-
cidence of hydrocephalus and cervical stenosis in pa-
tients with MPS IH is reported to be lower in those
treated with HSCT versus ERT [71]; however, as cogni-
tive deficits similar to those seen in patients with MPS
IH have not been observed in patients with MPS VI, it is
unclear whether HSCT would be an effective treatment
for MPS VI.
Evidence supporting the use of HSCT in patients with
MPS VI is currently lacking, being based on a small
number of case studies and results from non-
randomised follow-up studies [72–76]. Evidence from
case studies in patients with MPS VI suggests that
HSCT increases the enzymatic activity of N-acetylgalac-
tosamine 4-sulfatase in circulating white blood cells, and
has a positive effect on joint mobility, ENT and cardiac
manifestations, movement, QoL, as well as reducing fa-
cial dysmorphism [72]. Normalisation of urinary GAG
and dermatan sulphate levels and slowed disease pro-
gression have been observed in patients with mild MPS
VI phenotypes, with variable outcomes observed in vis-
ual acuity [77, 78]. There are limited survival data
post-HSCT in patients with MPS VI. Although now
somewhat dated, results of a retrospective study of
HSCT outcomes in patients with MPS VI (for trans-
plants performed between 1982 and 2007) reported a
cumulative incidence of acute graft versus host disease
at 100 days of 36% and a probability of survival of 78%
at 100 days and 66% at both 1 and 3 years [76]. The col-
laborative efforts of the transplant community have re-
sulted in a decline of the risks associated with transplant
across MPS [79, 80]; however, mortality rates still vary
between centres, and serious risks, including death, re-
main. It is the opinion of the expert SC that risks may
be higher in less experienced centres and it is therefore
critical that HSCT is only performed in centres dedi-
cated to transplant with access to an MDT with experi-
ence of managing patients with MPS. Matched donors
should preferably not be carriers for MPS VI, and unre-
lated donors should be well-matched.
Overall, the expert consensus was that the risk–benefit
profile of HSCT in patients with MPS VI is less clear
than in other types of MPS, and further research, specif-
ically, a well-designed comparative study of HSCT and
ERT in patients of similar age and disease severity is
needed to better understand the long-term efficacy and
safety of HSCT in patients with MPS VI.
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Considerations for monitoring response It is import-
ant to consider the life-long impact of HSCT on an indi-
vidual basis, as the benefits of treatment manifest
differently between each patient. Assessments should be
performed prior to, and at least annually, after HSCT to
measure the impact of transplantation on disease pro-
gression. Assessments should include: endurance testing,
cardio-respiratory function (owing to the significant car-
diac symptoms in patients with MPS VI), and measure-
ment of height and weight. Follow-up should also
include assessment of orthopaedic, ophthalmic, ENT,
neurological and endocrine function. Data should be
collected and shared in a manner that can advance the
understanding of the risks and benefits of HSCT.
Interventions to support respiratory and sleep disorders
Continuous positive airway pressure (CPAP), non-
invasive positive pressure ventilation (NIPPV),
oxygen supplementation and hypercapnia monitoring
(Table 6)
Rationale and evidence base Upper airway obstruc-
tion leading to obstructive sleep apnoea [81] is a common
morbidity in patients with MPS VI and can significantly
affect functional status and QoL [14, 82]. Typical features
of MPS VI include upper and lower airway obstruction
and restrictive pulmonary disease that occur from a
variety of anatomic and functional abnormalities [83].
Upper airway obstruction is attributable to cranial abnor-
malities, a short neck and progressive deposition of GAGs
in the tissues surrounding the supraglottic upper respira-
tory tract, while lower airway obstruction reflects GAG
deposition in the airway walls with resultant tracheal and
bronchomalacia. Lung volume and chest expansion are
further limited by short stature, chest wall deformities and
abdominal organomegaly [84].
A comprehensive review of the evaluation and treat-
ment options for sleep disordered breathing (SDB) in
MPS has been recently published [85]. Continuous posi-
tive airway pressure (CPAP) prevents upper airway col-
lapse during inspiration and is the mainstay of treatment
for OSA in the general population with beneficial effects
on blood pressure, cardiac events, mortality and QoL
[86]. Recent studies have demonstrated effectiveness of
CPAP in patients with MPS, showing improvement in
pulmonary hypertension and cardio-respiratory failure
[87–89]. An alternate form of therapy is required for pa-
tients who demonstrate either persistent OSA despite
CPAP or hypoventilation during sleep. Non-invasive
positive pressure ventilation (NIPPV) provides an in-
creased pressure during the inspiratory phase of breath-
ing to augment ventilation.
Supplemental oxygen can be prescribed for individuals
that demonstrate persistent nocturnal oxygen
Table 5 Guidance statements for HSCT
Statement Percentage
consensus
With consideration of the associated risks of morbidity and mortality associated with this procedure, HSCT may be an option
for patients with MPS VI who have a matched related donor (or unrelated donor), or cord blood grafta
Evidence Grade: C (consistent with level 4 studies and extrapolations from level 3 studies)
86%
Due to the risk of mortality, it is critical that HSCT is only performed in an institution with a multidisciplinary team experienced
in the care of patients with MPS VI
Evidence Grade: D (level 3/4 studies with inconsistent risk/benefit results)
91%
Post-consensus comments by the SC to be taken into consideration
aHSCT may be an option for patients with MPS VI who have a matched related donor (preferably not a carrier) or a well-matched adult unrelated donor
Table 6 Guidance statements for CPAP, NIPPV, oxygen supplementation and hypercapnia monitoring
Statement Percentage
consensus
CPAP therapy is recommended for patients with MPS VI who display the presence of obstructive sleep apnoea (OSA)
which persists after tonsillectomy and/or adenoidectomy
Evidence Grade: B (extrapolations from level 1 studies)
100%
NIPPV therapy is recommended for patients with MPS VI who display nocturnal hypoventilation and are unresponsive
to CPAP, or display daytime hypoventilation with increased PaCO2 and/or serum HCO3 levels
Evidence Grade: B (extrapolations from level 1 studies)
94%
Oxygen supplementation is recommended for patients with MPS VI who display sleep apnoea with nocturnal hypoxemia
and who do not tolerate CPAP or NIPPV masks
Evidence Grade: B (extrapolations from level 1/3/4 studies)
83%
Patients with MPS VI should be monitored for development of hypercapnia after starting oxygen therapy with measurement
of PaCO2 and/or serum HCO3
Evidence Grade: D (level 5, expert clinical opinion)
97%
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desaturation and for patients who do not tolerate therapy
with CPAP or NIPPV. Caution is required when prescrib-
ing oxygen because of the known complication of sup-
pressing respiratory drive and arousal from sleep with
potential for either worsening a pre-existing hypercapnia
or inducing onset of hypercapnia is susceptible patients.
Considerations for management SDB can be managed
by application of CPAP which delivers air at an elevated
pressure via a mask that fits around the nose and/or
mouth; however, consideration should be given to facial
abnormalities that can make mask fitting difficult. Patients
should be monitored to ensure they do not develop sus-
tained hypoventilation. Vaccinations against respiratory
pathogens causing influenza and pneumococcus infections
are recommended.
Anaesthetics and surgical interventions
Use of anaesthesia in patients with MPS VI (Table 7)
Rationale and evidence base Patients with MPS VI
will likely require anaesthesia for multiple surgical inter-
ventions and investigations to manage their disease [90,
91], but are considered high-risk for anaesthesia due to
potential airway difficulties with mask ventilation and/or
endotracheal intubation. Other risk factors include the
presence of narrow airways due to adenotonsillar hyper-
trophy, macroglossia and deformity of the lower airway,
skeletal abnormalities, pulmonary disposition and cardiac
and neurological impairment [14, 92, 93]. Intubation and
extubation can be challenging due to restricted mouth
opening, short neck length with a limited range of motion,
airway abnormalities already mentioned, micrognathia,
subglottic narrowing, and atlanto-axial instability due to
odontoid hypoplasia and ligamentous laxity [94–96]. Al-
though hypothetical, poor perfusion related to arterial nar-
rowing and reduced foramina diameters secondary to
dysostosis should be anticipated by an anaesthetist, be ap-
propriately monitored with arterial lines, and supported in
the near-normal range during procedures.
Adverse events (including fatalities and paralysis) oc-
curring during anaesthesia of patients with MPS have
been reported in the literature [97]. Although data on
peripheral nerve blocks are lacking, this approach may
be considered, and use of ultrasound technology can as-
sist successful performance of these procedures and may
allow avoidance of general anaesthesia in selected
Table 7 Guidance statements for anaesthesia
Statement Percentage
consensus
Pre-, intra- and post-operative care (until extubation is complete) for all procedures requiring general anaesthesia, conscious
or deep sedation, should be supervised by an anaesthetist with experience in treating patients with MPS and/or complex
airway management. In addition, the anaesthetist should have access to Intensive Care support and be surrounded by an
experienced team capable of performing emergency tracheotomy if required
Evidence Grade: C (level 3/4 studies)
98%
A full assessment of the risks and benefits should take place with the patient and family prior to any procedure. All pre-operative
information should be made available to allow decision making
Evidence Grade: C (level 4 study and extrapolation from level 3 study)
100%
ENT respiratory, cardiac, and radiological assessment should be performed prior to any procedure requiring anaesthesia
Evidence Grade: C (level 3 study and extrapolation from level 3 study)
93%
It is critical to maintain a neutral neck position during all surgeries, and during intubation and extubation to avoid paralysisa.
Strongly recommend the use of techniques that allow maintenance of the neutral neck position, including use of laryngeal
mask airway (LMA) for shorter procedures, or intubation with a video laryngoscope or fibreoptic intubation
Evidence Grade: C (level 3/4 studies)
87%
Pre-operative and intra-operative measures to avoid hypotension should be adopted during all surgical procedures in patients
with MPS VI to maintain spinal cord perfusion and therefore protect spinal cord function
Evidence Grade: D (expert clinical opinion)
98%
Intra-operative neurophysiological monitoring (including somatosensory evoked potentials [SSEP], electromyography [EMG] and
motor evoked potentials [MEP]) is strongly recommended during all spinal surgeries and other potentially lengthy or complicated
procedures, including those that require manipulation of the head and neck
Evidence Grade: D (limited published evidence)
94%
For other surgeries and procedures, neurophysiologic monitoring should be considered based on pre-existing risk for spinal cord
compression and instability, need for spine manipulation, possibility of hemodynamic changes and blood loss, or extended length
of time
Evidence Grade: D (limited published evidence)
94%
Intrathecal and epidural techniques should be used with extreme caution in patients with MPS VI, due to the anatomical
challenges of very short stature, as well as spinal abnormalities causing insertion problems and unpredictability of spread of
local anaesthesia. However, these techniques may be considered to avoid general anaesthesia in a high-risk situation or
during pregnancy
Evidence Grade: D (expert clinical opinion)
88%
Post-consensus comments by the SC to be taken into consideration
aIt is critical to maintain a neutral neck position to avoid any spinal cord injury
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patients. Perioperative neurophysiological monitoring is
recommended to prevent significant complications in
this high-risk population; however, availability worldwide
is extremely variable.
Considerations for anaesthesia Due to the risk of
upper airway obstruction, pre-operative sedative pre-
medication should be used with caution in patients with
MPS VI and only with appropriate monitoring. Assessment
of the upper and lower airways anatomy (for example, a
pre-operative flexible nasopharyngolaryngoscopy and
three-dimensional computerised tomography (CT) scan of
the trachea, where feasible), cardiac function (including an
ECG and echocardiogram), and potential cervical spine in-
stability and compression, should be performed and func-
tion as baseline evaluation prior to any procedure that
requires sedation or anaesthesia. This needs to be repeated
at a future date with increase in age and weight. Similarly,
MRI scans of the spine in a neutral position or a flexion/ex-
tension X-ray of the spine can be performed to assess the
risk of spinal cord compression and instability (flexion/ex-
tension X-ray measures instability only). Flexion/extension
imaging of the cervical spine prior to anaesthesia is re-
quired to assess atlantoaxial instability. The frequency of
imaging should be dependent on both the patient’s age and
clinical condition. To avoid spinal cord injury, sensory in-
jury with dysesthetic pain, and/or loss of proprioception, it
is critical to maintain a neutral neck position during all sur-
geries, including intubation and extubation. The aim is to
avoid spinal cord injury which can lead to paralysis. When
possible, intubation should be completed while patients are
breathing spontaneously, and the use of paralytic agents
should be avoided such that spontaneous breathing is
maintained until intubation is completed successfully. Use
of a smaller endotracheal tube size is usually necessary and
often critical, to avoid intraoperative swelling of the airway
and enable successful extubation. Where possible, patients
should be extubated in the operating room (OR) and asked
to demonstrate movement of all extremities. If safe intub-
ation cannot be achieved, tracheostomy may be considered
electively prior to prolonged surgery, or to facilitate
post-operative care. If the patient is awake or breathing
spontaneously, the option of delaying the surgery after
failed intubation should be considered. Mean arterial pres-
sure should be maintained to maximise perfusion of the
spinal cord and reduce the risk of spinal cord injury. Dis-
placing the tongue anteriorly prior to intubation by manual
retraction using a ring forceps or a piece of gauze may help
to access the larynx in children with MPS VI [94]. Intensive
care management is often not required but may be neces-
sary for complicated or prolonged procedures requiring
post-operative ventilation or peri-operative tracheostomy. If
ventilated via an endotracheal tube, it is best to aim for
early extubation to minimise swelling of the airway. When
clinically indicated, maintenance of intubation overnight
following the procedure may be considered to allow reso-
lution of any airway swelling. Extubation should be per-
formed by an experienced anaesthetist who can assess the
airway before extubation and if necessary reintubate in the
intensive care unit (ICU) or OR. Wherever possible, alter-
native techniques (e.g. peripheral nerve block under light
sedation) should be considered to avoid general anaesthesia
and the associated risks thereof. However, the surgical team
should always be prepared to perform general anaesthesia
when required.
Considerations after surgery Intraoperative use of
steroids to reduce airway oedema is standard and the use of
post-operative treatment may also be necessary for 24 h.
Standard treatment for patients with upper airway obstruc-
tion should be available, including NIPPV, CPAP, and con-
tinuous monitoring of respiratory and cardiac function.
ICU stays are not mandatory for all patients after all surger-
ies and should only be used when needed; nonetheless,
availability of ICU facilities for management of complica-
tions, is critical. Intensive monitoring is required for 24–48
h post-surgery because of the potential complications of
oral secretions, thoracic cage stiffness and heart and lung
failure, which can include apnoea, laryngospasm, broncho-
spasm, cyanosis and respiratory failure.
Limb surgeries in patients with MPS VI (Table 8)
Rationale and evidence base MPS VI is characterised
by profound skeletal dysplasia with cervical spinal canal
stenosis, hip abnormalities and genu valgum [98]. Hip
problems can lead to severe disability [23]. Patients with
MPS VI have progressive musculoskeletal involvement,
and numerous orthopaedic interventions are usually re-
quired to prevent deformity, improve function and reduce
pain. Evidence from a prospective follow-up study showed
that clinically significant hip abnormalities develop in all
patients with MPS VI from very early on in life, starting
with deformities of the os ilium and acetabulum. Femoral
head abnormalities occur later and are most likely due to
altered mechanical forces in combination with epiphyseal
abnormalities due to GAG storage, however, the final
shape and neck shaft angle differs significantly between in-
dividual patients and is difficult to predict [23]. Case stud-
ies based on two patients with MPS I with skeletal
dysplasia and thoracic kyphosis showed a rare complica-
tion of the spinal cord injury. This reiterated the import-
ance of careful pre-operative assessments, including MRI
of the spine, to reduce the risk of spinal cord injury [99].
Guided growth techniques for correction of genu
valgum are not widely reported in patients with MPS VI;
however, the indications for this approach need recon-
sideration in the era of ERT. A recent report of guided
growth surgery conducted in two children with MPS VI
while receiving ERT suggest that that this may be a
useful approach to correcting knee deformities [98].
Akyol et al. Orphanet Journal of Rare Diseases          (2019) 14:118 Page 12 of 21
Patient selection for intervention Most patients with
MPS VI will have abnormal radiographic findings; there-
fore, hip surgery should only be considered in patients who
are symptomatic, as determined by presence of hip pain
resulting in much reduced mobility and endurance. Growth
modulation surgery should be initiated as soon as the de-
formity is observed, or if the tibial-femoral angle is > 15 de-
grees. For optimal results, it should be performed early
during the period of growth, due to the deceleration in
growth that occurs as the skeleton matures [100], however
expert clinical opinion varies regarding the ideal age to per-
form the surgery. The period following ERT commence-
ment may also be a good time to perform growth
modulation surgery. Before orthopaedic intervention, mor-
bidity and mortality risks, pain level, optimal timing and pa-
tient preference should be considered on a case-by-case
basis.
Currently there is no hand surgical intervention that
can be recommended to improve the weakness of the grip
but maintain vital flexibility for transfer and adequate
ADL. External custom-made splints can be worn to help
with certain tasks e.g. heavy lifting. Occupational thera-
pists are vital to help with ADL including providing gad-
gets to perform necessary tasks. Patients with weak grip
can learn to adapt to master necessary ADL.
Considerations for surgery All surgeries should be su-
pervised by an anaesthetist with experience in treating MPS
and/or complex airway management (refer to the anaes-
thetics recommendations). Limb surgeries should be per-
formed by an orthopaedic surgeon with a basic
understanding of MPS and of the clinical presentation,
musculoskeletal abnormalities, and radiographic findings
associated with this group of disorders. An overnight hos-
pital stay is recommended following hip surgery to allow
access to intensive care, should this be needed, although
this may not be necessary for surgeries such as
hemi-epiphysiodesis. Long-term, intensive physical therapy
is recommended post-surgery to enhance recovery, and as-
sessment should be performed regularly as patients may re-
quire repeated surgeries/interventions. The primary goal of
limb surgery is not to improve or restore joint range of mo-
tion (ROM), but rather to reduce pain or improve mobility.
Goniometer measurements performed by a physiotherap-
ist/occupational therapist/rheumatologist may be useful but
may not be available in all centres.
Spinal surgeries in patients with MPS VI (Table 9)
Rationale and evidence base Skeletal abnormalities
are early and prominent features of MPS VI and are po-
tentially debilitating and life-threatening [14, 53]. Medical
therapies for the management of MPS have a limited ef-
fect on the development of skeletal deformities; therefore,
early surgical intervention is important to manage disease
progression [100, 101]. The frequency of spinal cord com-
pression and the success of surgical intervention has been
reported by a clinical surveillance programme [102]. Rou-
tine neurological history, examination and appropriate im-
aging should be part of standard care to detect early
compromise of the spine.
Patient selection for intervention Indications for sur-
gery include cervical spine cord compression as deter-
mined by clinical symptoms (including weakness,
numbness, paraesthesia, and gait difficultly) or radio-
graphic and MRI findings (including plain radiographic
findings suggestive of stenosis and instability and MRI
findings of extradural stenosis, cord compression, mye-
lomalacia and instability). Physicians should consider the
timing of such surgery in line with the need for cardiac
valve replacement, as the latter procedure could subse-
quently commit the patient to lifetime anticoagulation
therapy.
Considerations for surgery Spinal surgeries should be
performed by a neurosurgeon and/or spinal surgeon with
a basic understanding of MPS and of the clinical presenta-
tion, musculoskeletal abnormalities, and radiographic
findings associated with this group of disorders.
Ophthalmic surgery in patients with MPS VI (Table 10)
Rationale and evidence base Corneal opacification
leading to reduced visual acuity is a common feature in
patients with MPS VI and does not appear to be influ-
enced by ERT. Other ophthalmic findings in patients with
MPS VI include high hyperopia, increased corneal thick-
ness, optic nerve abnormalities, ocular hypertension,
Table 8 Guidance statements for hip replacement, hip reconstruction and growth modulation surgery
Statement Percentage
consensus
Hip replacement can be considered in adult patients with MPS VI who exhibit hip pain, reduced walking and endurance
related to hip disease, as well as abnormal radiographic findings
Evidence Grade: D (limited published evidence)
100%
Hip reconstruction is not routinely indicated, but may be considered in paediatric patients with MPS VI who exhibit hip pain,
reduced walking and endurance related to hip disease, as well as abnormal radiographic findings
Evidence Grade: D (limited published evidence)
92%
Growth modulation surgery is recommended in patients with MPS VI who have signs of genu valgum and should be performed
as early as possible during the period of growth
Evidence Grade: D (limited published evidence)
87%
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glaucoma, and rarely, retinopathy [103, 104]. Clear corneal
grafts can be achieved for patients with MPS VI who have
corneal clouding, and may result in improvements in vis-
ual acuity [105]. Rejection episodes have been reported
following corneal transplantation in patients with MPS VI;
however, it should be noted that most occurred in those
who were transplanted at a younger age (13–28 years old)
[105, 106]. Generally, the recurrence of corneal deposits
has not been reported in patients with MPS VI [105, 106].
Patient selection for intervention Corneal transplant-
ation can be considered if corneal clouding is of such se-
verity that it causes significant loss of vision and impacts
QoL. The decision to perform corneal transplantation
should be made on a case-by-case basis and should only
be considered once retinopathy and optic nerve abnor-
malities have been assessed using electrodiagnostic (in-
cluding electroretinography and visual evoked potentials)
and have been excluded as a significant contributing factor
to the loss of vision. The choice of surgical technique for
corneal transplantation (deep anterior lamellar kerato-
plasty [DALK] or penetrating keratoplasty [PK]) should be
made on a case-by-case basis. There is some evidence
from the general population to suggest that rejection is
more likely to occur following PK than DALK [106–108];
as such, DALK should be considered as the first approach
in patients with MPS VI.
Considerations for intervention (e.g. if surgery)
Monitored anaesthesia care with appropriate sedation and
support with nasal CPAP/NIPPV may be used when per-
forming eye surgery in patients with MPS VI. Signs of re-
jection require prompt ophthalmic assessment to prevent
graft failure. Following corneal transplantation, long-term
topical treatment is needed, as is regular (annual) ophthal-
mic assessment to determine the health of the corneal graft,
assess for recurrence of corneal deposits and astigmatism
control. Follow-up is also required to monitor for optic
neuropathy due to raised intracranial pressure. This can be
indicated by a reduction in visual acuity, new onset of visual
field defect, abnormal pupil reactions, new onset of optic
nerve swelling or (more commonly) optic atrophy and vis-
ual evoked potential abnormality.
Carpal tunnel decompression in patients with MPS
VI (Table 11)
Rationale and evidence base Carpal tunnel syndrome
(CTS) is a common condition in patients with MPS VI,
which if left untreated, can lead to loss of nerve function.
Trigger finger can also present in association with CTS in
patients with MPS VI. Surgical decompression of CTS, es-
pecially when performed early, has reduced signs and
symptoms of compressive myelopathy and improves the
chance of preserving hand function [109, 110]. Evidence, al-
beit from limited case studies in patients with MPS, sug-
gests that clinical improvements in hand/motor function,
dexterity and spontaneous hand function are observed after
carpal tunnel decompression (CTD), which are coupled
with reduction in long-term hand pain and cessation of
night pain [109]. The preservation of hand function re-
quires a combination of steps including decompression of
the median nerve, tenosynovectomy and if necessary, an
A1 and A3 pulley release rather than decompression alone.
There are no data to suggest that an approach using teno-
synovectomy alone is beneficial compared with tenosyno-
vectomy plus complete epineurectomy; however, in rare
Table 9 Guidance statements for decompression of the spinal cord, spinal stabilisation and thoracolumbar kyphoscoliosis
Statement Percentage
consensus
Decompression of the spinal cord is recommended in patients with MPS VI who have evidence of spinal cord compression
based on clinical and radiographica findings
Evidence Grade: D (limited published evidence)
97%
Spinal stabilisation of the craniocervical junction with either cervical fusion or occipital-cervical fusion is recommended in
patients with MPS VI who have evidence of significant instability
Evidence Grade: D (expert clinical opinion)
100%
Correction of thoracolumbar kyphoscoliosis is recommended in patients with MPS VI who present with progressive radiographic
changes, intractable pain and clinical deterioration as defined by gait, lung function and changes in the degree of kyphosis
Evidence Grade: D (limited published evidence)
97%
Post-consensus comments by the SC to be taken into consideration
aThe SC would like to clarify that neuroimaging is a required radiologic procedure to define compression. MRI is best to image the brain and spinal cord for this
indication. Decompression of the spinal cord is recommended in patients who have evidence of spinal cord compression and risk of injury based on clinical and
neuroimaging findings
Table 10 Guidance statement for corneal transplantation
Statement Percentage
consensus
Corneal transplantation can be considered for patients with MPS VI who have significant visual loss attributed to
corneal opacification
Evidence Grade: B (extrapolations from level 1/3/4 studies)
100%
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cases, epineurotomy may be useful to achieve more effect-
ive decompression. Recurrence is frequent in older patients
therefore repeated surgery may be indicated.
Patient selection for intervention CTD should be
performed in patients who display restriction of hand
function, including increased flexion contracture of the
PIP and DIP joints, indicative of an increase in ‘scarred’
and tethered subsynovial connective tissue around the
flexor tendons in the carpal canal. Clinical symptoms of
hand pain/numbness include night pain, biting and/or
slapping of fingers and pain or numbness in the thumb,
index or middle finger. It is important to note that if a
patient reports numbness in all fingers it is unlikely to
be CTS, and pain in the little finger is suggestive of com-
pression higher up than the carpal canal. Neurophysio-
logical tests should be performed to rule out cervical
compression before initiating surgery.
Considerations for surgery CTD should be performed
by a hand surgeon with a basic understanding of MPS and
of the clinical presentation associated with this group of
disorders. In most cases, CTD may be performed with re-
gional block plus sedation, with or without the use of LMA.
Considerations for post-surgery monitoring Regular
post-surgical physical therapy may facilitate maintenance of
increased hand movement. All patients who undergo CTD
surgery should be assessed (pre- and post-surgery) for QoL,
improvement in ROM and self-reported change in
function.
Cardio-thoracic surgery in patients with MPS VI
(Table 12)
Rationale and evidence base Cardiac valve disease,
which occurs as a result of valve thickening from depos-
ition of storage material, occurs commonly in patients with
MPS VI [111] and is a major cause of morbidity and mor-
tality. Cardio-thoracic surgery in patients with MPS VI can
be challenging because of small patient size and associated
skeletal and pulmonary co-morbidities. Evidence from sev-
eral case reports and small case series suggests that replace-
ment of the aortic and mitral valves, either singly or in
combination, is feasible in patients with MPS VI [112–116].
Successful resection of a left ventricular apical aneurysm, a
rare complication of MPS VI, has been reported [117], but
successful balloon dilation of aortic or mitral valves has not.
Patient selection for intervention (refer to the recom-
mendations for routine assessments and monitoring)
The performance and interpretation of findings of echo-
cardiography should be completed by individuals familiar
with the expected pathological findings in patients with
MPS VI. Valve replacement decisions should be based on
current European/American (AHA) guidelines [118, 119]
in conjunction with assessment of existing co-morbidities,
operative risk and rehabilitation potential. Trans-catheter
aortic valve replacement may be appropriate for some pa-
tients with MPS VI. The Ross procedure is contraindicated
in patients with systemic valvular disease. Small valve
annulus may preclude valve replacement with currently
existing mechanical and bio-prosthetic cardiac valves.
Consideration for surgery Cardiac surgery in patients
with MPS VI should be performed in a centre of excel-
lence with a team experienced in both managing patients
with MPS and performing high-risk valve replacement
surgery. When possible, an anaesthetic specialist with ex-
perience in managing patients with MPS should assist the
cardiac anaesthetic team during pre-operative assessment
in formulating an MPS-related anaesthesia care plan.
Similarly, the anaesthetic care plan for cardiac catheterisa-
tion should be formulated jointly by the cardiologist and
anaesthetic care team specialist. Airway care, including
the need for tracheostomy, should be assessed on a
case-by-case basis.
Ear, nose and throat surgery in patients with MPS VI
(Table 13)
Rationale and evidence base ENT manifestations are
common in patients with MPS VI and often involve hearing
disorders, otitis media and upper airway obstruction [14].
Permanent hearing loss is common and is believed to be
conductive and neurosensory in nature [14, 120]. Results
from two non-randomised studies revealed that ENT sur-
gery reduced hypoacusia, otitis media, incidence of upper
respiratory tract infections, occurrence of OSA and need
for Type B tympanograms. QoL was also reported to be im-
proved in some patients [82, 121]. The results from another
non-randomised study suggest that tonsillectomy and/or
adenoidectomy significantly improves post-operative sleep
apnoea in MPS patients [82]. Development of secondary
haemorrhage is a serious risk associated with tonsillectomy
Table 11 Guidance statements for decompression of the median nerve, tenosynovectomy and pulley release
Statement Percentage
consensus
Decompression of the median nerve and tenosynovectomy of all flexor tendons in the carpal tunnel is recommended in
patients with MPS VI who display flexion contractures and distal interphalangeal (DIP) joints and/or proximal interphalangeal
(PIP) joints (clawing), as well as clinical symptoms of hand pain and/or numbness in the thumb to middle finger, and in
patients with positive nerve conduction studies
Evidence Grade: C (level 4 studies)
89%
A1 and A3 pulley release is recommended in patients with MPS VI who display obvious trigger finger
Evidence Grade: C (level 4 studies)
94%
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and/or adenoidectomy in patients with MPS as difficult in-
tubations are common in these patients and can be fatal
[82, 122]. Evidence from a case series shows that insertion
of ventilation tubes can improve air and bone conduction
and the air-bone gap in patients with MPS VI [39]. Ad-
vanced surgical options such as uvulopalatopharyngoplasty
(UPPP), mandibular advancement surgery and tongue
reduction are currently experimental. While one member
of the SC had experience, currently, there is not enough
evidence from which to derive any recommendations
about the use of these invasive procedures in patients with
MPS VI.
Considerations for surgery Vaccinations against re-
spiratory pathogens causing influenza and pneumococ-
cus infections are recommended to prevent pneumonia.
Insertion of ventilation tubes should be performed ac-
cording to the guidelines for the general paediatric
population [123, 124]. Patients who have had tonsillec-
tomy and/or adenotonsillectomy should be observed as
in-patients and may need to remain in hospital prefera-
bly in intensive care in the early post-operative period to
monitor airway patency. They may need to remain hos-
pitalised for additional days to allow close monitoring
for possible haemorrhage and other complications. Pa-
tients with ventilation tubes should be assessed every
three months and if improvement in hearing is absent, a
post-operative audiologic assessment should be per-
formed. The anaesthesia plan should be discussed jointly
between the otolaryngologist and anaesthesia care team
and precautions should be taken to prevent spinal cord
compression during surgical procedures. However, be-
fore performing tonsillectomy, children with MPS
should be referred by the clinician for polysomnography
for sleep [125].
Discussion
Where evidence is scarce, systematic approaches are re-
quired to ensure the evidence-base is as extensive as
possible. This programme involved a validated system-
atic approach to the development of guidance state-
ments and the resulting publication therefore addresses
this unmet need by creating a robust, holistic set of rec-
ommendations for healthcare professionals managing
patients with MPS VI. A detailed discussion on the devel-
opment of the guidance methodology, strengths and limi-
tations of the programme, future directions, facilitators/
barriers to support the application of the guidance includ-
ing cost considerations, and conclusions is provided in the
discussion of the companion article of this publication
(Recommendations for the management of MPS IVA:
systematic evidence- and consensus-based guidance).
Conclusions
This manuscript provides robust evidence- and consen-
sus-driven guidance for the management of patients with
MPS VI. The guidance is intended for use by healthcare
professionals that manage the holistic care of patients with
MPS with the intention to enhance patient quality of life
and improve clinical- and patient-reported outcomes. It
recognised that the guidance provided represents a point
in time and further research is required to address current
knowledge/evidence gaps. The SC recommends that this
guidance is reviewed and updated within 5 years, or
sooner if there are significant changes to medical practice.
Table 12 Guidance statements for cardiac valve replacement, left ventricular apical aneurysms and tracheostomy
Statement Percentage
consensus
Cardiac (aortic, mitral) valve replacement should be considered in patients with MPS VI who display symptomatic
and severe valve stenosis or regurgitation
Evidence Grade: C (level 4 studies)
100%
Left ventricular apical aneurysms occur rarely in patients with MPS VI, but should be resected whenever possible
Evidence Grade: D (limited published evidence)
85%
Table 13 Guidance statements for tonsillectomy and/or adenoidectomy, tracheostomy and insertion of ventilation tubes
Statement Percentage
consensus
Tonsillectomy and/or adenoidectomy is recommended in patients with MPS VI who display upper airway obstruction, recurrent
otitis media, snoring and/or OSA, as early as possible following diagnosis without waiting for disease progression
Evidence Grade: C (level 2/3/4 studies)
91%
Tracheostomy is recommended in patients with MPS VI who exhibit severe upper airway obstruction that cannot be treated by an
alternative approach, and in patients with severe sleep apnoea that is not treatable by CPAP or tonsillectomy and/or adenoidectomy
Evidence Grade: D (limited published evidence)
95%
Insertion of ventilation tubes is recommended for patients with MPS VI with otitis media with effusion and/or recurrent otitis media
to maintain hearing and/or prevent recurrent acute otitis media
Evidence Grade: D (limited published evidence)
96%
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